M3/M21 serum levels in women with adnexal masses and inflammatory diseases

International Journal of Cancer

Volumn 79, Issue 4, 1998, Pages 434-438

  Hefler, Lukas ^a   Tempfer, Clemens ^a   Heinzl, Harald ^a   Haeusler, Guenther ^a   Steindl, Petra ^a   Schneeberger, Christian ^a   Gitsch, Gerald ^a   Kainz, Christian ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN; EPITOPE; MONOCLONAL ANTIBODY; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER SCREENING; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; ENDOMETRIOSIS; ENTERITIS; FEMALE; GYNECOLOGIC CANCER; HUMAN; HUMAN TISSUE; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; OVARY CANCER; OVARY CYST; PELVIC INFLAMMATORY DISEASE; PRIORITY JOURNAL; PROGNOSIS; SERUM;

ADENOCARCINOMA; ADULT; AGED; CARCINOMA; ENDOMETRIOSIS; EPITOPES; EVALUATION STUDIES; FEMALE; HUMANS; KERATINS; MIDDLE AGED; OVARIAN DISEASES; OVARIAN NEOPLASMS; PELVIC INFLAMMATORY DISEASE; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 0031827697     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19980821)79:4<434::AID-IJC21>3.0.CO;2-3     Document Type: Article

References (21)

1. AMERICAN SOCIETY OF CLINICAL ONCOLOGY, Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. J. clin. Oncol., 14, 2843-2877 (1996).
2. BEREK, J.S., CHUNG, C., KALDI, K., WATSON, L.M., KNOX, R.M. and MARTINEZ-MAZA, O., Serum interleukin-6 levels correlate with disease status in patients with epithelial ovarian cancer. Amer. J. Obstet. Gynecol., 164, 1038-1042 (1991).
3. BJÖRKLUND, B., Tissue polypeptide antigen (TPA). Biology, biochemistry, improved assay methodology, clinical significance in cancer and other conditions, and future outlook. Antibiot. Chemother., 22, 16-31 (1978).
4. BJÖRKLUND, B. and BJÖRKLUND, V., Specificity and basis of the tissue polypeptide antigen. Cancer Detect. Prev., 6, 41-50 (1983).
5. BODENMÜLLER, H., DONIE, F., KAUFMANN, M. and BANAUCH, D., The tumor markers TPA, TPS, TPAcyk, and CYFRA 21-1 react differently with the keratins 8, 18 and 19. Int. J. biol. Markers, 9, 70-74 (1994).
6. BORMER, O., From tissue polypeptide antigen to specific cytokeratin assays. Tumor Biol., 15, 185-187 (1994).
7. CARPELAN-HOLMSTROM, M., HAGLUND, C., LUNDIN, J., ALFTHAN, H., STENMANN, U.H. and ROBERTS, P.J., Independent prognostic value of preoperative serum markers CA 242, specific tissue polypeptide antigen and human chorionic gonadotropin beta, but not of carcinoembryonic antigen or tissue polypeptide antigen in colorectal cancer. Brit. J. Cancer, 74, 925-929 (1996).
8. DEVINE, P., All cytokeratin assays are not the same. Europ. J. clin. Chem. Clin. Biochem., 32, 939-940 (1994).
9. KAINZ, C., STEINER, G., GITSCH, G., SLIUTZ, G., MUSTAFA, G. and KOELBL, H., Tissue polypeptide specific antigen (TPS) in der biochemischen tumordiagnostik. Klin. Labor, 40, 999-1005 (1994).
10. MOLL, R., FRANKE, W.W., SCHILLER, D.L., GEIGER, B. and KREPLER, R., The catalog of human cytokeratins: patterns of expression in normal epithelia, tumours and cultured cells. Cell, 31, 11-24 (1982).
11. MOLL, R., LEVY, R., CZERNOBILSKY, B., HOHLWEG-MAJERT, P., DALLENBACH-HELLWEG, G. and FRANKE, W., Cytokeratins of normal epithelia and some neoplasms of the genital tract. Lab. Invest., 49, 599-610 (1983).
12. MORAGLIO, D., PAGANO, M., GALEAZZI, D., ARNELLI, A. and BERTERO, L., Tissue polypeptide specific antigen (TPS) in liver disease. Clin. chim. Acta, 224, 209-214 (1994).
13. QUINLAN, R.A., SCHILLER, D., HATZFELD, M., ACHSTÄTTER, T., MOLL, R. and JORCANO, J., Patterns of expression and organization of cytokeratin intermediate filaments. Ann. N.Y. Acad. Sci., 455, 282-306 (1985).
14. ROSE, P.G., SOMMERS, R.M., REALE, F.R., HUNTER, R.E., FOURNIER, L. and NELSON, B.E., Serial serum CA 125 measuremens for evaluation of recurrence in patients with endometrial carcinoma. Obstet. Gynecol., 84, 12-16 (1994).
15. RUSTIN, G., Circulating tumor markers in gynecological tumors. Curr. Opin. Oncol., 8, 426-431 (1996).
16. SABBATINI, S., MONTI, M. and FINI, A., Tissue polypeptide antigen (TPA) modifications in hepatic cirrhosis, aggressive chronic hepatitis, persistent chronic hepatitis, and in minimal pathology. Int. J. biol. Markers, 3, 127-128 (1988).
17. SEVELDA, P., ROSEN, A., DENISON, U., BARRADA, M., SPONA, J. and SALZER, H., Is CA 125 monitoring useful in patients with epithelial ovarian carcinoma and preoperative negative serum levels? Gynecol. Oncol., 43, 154-158 (1991).
18. TEMPFER, C., HANZAL, E., ZEILLINGER, R., KOELBL, H., DADAK, C. and KAINZ, C., The new serum tumor marker M3/M21 in the follow-up of breast cancer patients. Anticancer Res., 16, 2135-2138 (1996).
19. TEMPFER, C., HEELER, L., HAEUSLER, G., SLIUTZ, G., HANZAL, E. and KAINZ, C., Serum M3/M21 in ovarian cancer patients. Brit. J. Cancer, 76, 1387-1389 (1997).
20. TOUITOU, Y. and BOGDAN, A., Tumor markers in non-malignant diseases. Europ. J. Cancer clin. Oncol., 24, 1083-1091 (1988).
21. VAN NIEKERK, C.C., BOERMANN, O.C., RAMAEKERS, F.C. and POELS, L.G., Marker profile of different phases in the translation of normal human ovarian epithelium to ovarian cancer. Amer. J. Pathol., 138, 455-463 (1991).